As all of us know, there has been an alarming increase in the incidence of acinetobacter infections
At present, infections mostly occur in ICU/critically ill patients
Important risk factors for colonization and infection include mechanical ventilation, recent surgery, tracheostomy, residents of long-term care facilities, central venous catheterization, and enteral feedings
The most frequent clinical manifestations are ventilator associated pneumonia and bacteremia
Susceptible strains can be treated with a broad-spectrum cephalosporin, carbapenem, or B-lactam-B-lactamase used alone or in combination with an aminoglycoside
For resistant strains, the most active agent in vitro are the polymyxins
The most common adverse effect of the polymyxins is nephrotoxicity (up to 36%)
Tigecycline has been used but resistance rates are rapidly increasing
